About REGENXBIO Inc
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M.
Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Founding and Start-up
Growth
REGENXBIO Inc. is a leading clinical-stage biotechnology company that is currently in the scale-up phase of growth. They have established a strong foundation in the field of gene therapy and are focused on improving lives through the curative potential of their innovative treatments. The company is actively expanding its therapeutic pipeline and investing in cutting-edge science and innovation to drive their growth.
Achievements
REGENXBIO has achieved significant milestones in its history, including the development of gene therapy product candidates in the retinal, metabolic, and neurodegenerative therapeutic areas. The company has also been recognized for its exceptional work culture, receiving the Washington Post's Top Work Places award in 2021, 2022, and 2023. These achievements demonstrate the company's dedication to delivering impactful treatments and fostering a positive work environment.
Case Studies
REGENXBIO has been involved in numerous notable case studies and significant projects that have showcased the impact of their gene therapy treatments. These case studies have demonstrated the efficacy of their therapies in treating various diseases, highlighting the potential of gene therapy to revolutionize healthcare. The company's continued research and development efforts have led to groundbreaking advancements in the field of biotechnology, setting them apart as a leader in the industry.
Socials
Website
CEO
Curran M. Simpson
Founded
-
Operating Status
Active
Industry
Health Care/Life Sciences
headquarters
Address
9804 Medical Center Drive Rockville Maryland 20850 United States...
Country
United States
Employees
344
Key People
Alexandra Glucksmann (Independent Director)
Kenneth T. Mills (Chairman)
Mitchell Chan (Executive VP, Chief Financial & Accounting Officer)
Revenue
90.24 M
Operating Income
Stock Price
$9.35
Why Setting Up a Virtual Delivery Center (VDC) Is Critical for Your Company’s Success
Achieving business success in today’s competitive landscape requires specialized expertise, seamless operations, and continuous innovation. Establishing a Virtual Delivery Center (VDC) can transform your company’s growth journey by ensuring efficiency, scalability, and long-term value.
Why Choose a VDC for Your Company?
1. Cost Optimization:
Save up to 70% on operational costs by leveraging remote teams and streamlined processes.
2. Expert Access:
Gain instant access to highly skilled professionals, ensuring faster and smoother project execution.
3. Scalable Teams:
Scale your team as business needs evolve, from initial project setup to long-term support.
4. Accelerated Timelines:
Leverage 24/7 global teams to reduce project delays and speed up implementation.
5. Continuous Support:
Ensure uninterrupted business performance with ongoing maintenance and updates.
Unlock Business Success with a VDC By establishing a VDC, your company can overcome operational challenges, achieve seamless system integration, and maximize ROI. Stay ahead in today’s dynamic market with a future-ready business strategy powered by a Virtual Delivery Center.
Book A Meeting To Setup A VDC
Welcome to AiDOOS Wiki
AiDOOS Information Wiki provides comprehensive information about products, companies, and individuals.
-
Formerly
-
-
Founded
-
-
Founder
-
-
Headquarters
-
Revenue
90.24 M
-
Operating income
-
-
Net income
-
-
Number of employees
344+
-
Website
-
About REGENXBIO Inc
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Founding and Start-up
Growth
...
